Cargando…

Efficacy of prednisone 1–4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial

OBJECTIVE: A randomised double-blind placebo controlled withdrawal clinical trial of prednisone versus placebo in patients with rheumatoid arthritis (RA), treated in usual clinical care with 1–4 mg/day prednisone, withdrawn to the same dose of 1 mg prednisone or identical placebo tablets. METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pincus, T, Swearingen, C J, Luta, G, Sokka, T
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Group 2009
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756955/ https://www.ncbi.nlm.nih.gov/pubmed/19074913 http://dx.doi.org/10.1136/ard.2008.095539

Ejemplares similares

Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study
por: Buttgereit, Frank, et al.
Publicado: (2019)

Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial
por: Smolen, J S, et al.
Publicado: (2015)

Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)
por: Buttgereit, Frank, et al.
Publicado: (2013)

Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis
por: Buttgereit, Frank, et al.
Publicado: (2010)

MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study
por: Peterfy, Charles, et al.
Publicado: (2016)

Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial
por: Brunner, Hermine I, et al.
Publicado: (2018)

Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial
por: Brunner, Hermine I, et al.
Publicado: (2015)

Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
por: Kay, Jonathan, et al.
Publicado: (2015)

Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs
por: Sokka, Tuulikki, et al.
Publicado: (2008)

Prednisone and Prednisolone in the Treatment of Rheumatoid Arthritis
por: Montgomery, D. A. D.
Publicado: (1957)

Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study
por: Burmester, Gerd R, et al.
Publicado: (2011)

Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States
por: Sokka, T., et al.
Publicado: (2008)

Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
por: Mease, Philip J, et al.
Publicado: (2017)

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial
por: Brunner, Hermine I, et al.
Publicado: (2023)

Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis
por: Alten, Rieke, et al.
Publicado: (2015)

Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial
por: Taylor, Peter C, et al.
Publicado: (2011)

A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis
por: Smolen, Josef S, et al.
Publicado: (2017)

Maternal Deworming Research Study (MADRES) protocol: a double-blind, placebo-controlled randomised trial to determine the effectiveness of deworming in the immediate postpartum period
por: Mofid, Layla S, et al.
Publicado: (2015)

MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16
por: Østergaard, M, et al.
Publicado: (2015)

Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose–response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
por: Takeuchi, Tsutomu, et al.
Publicado: (2016)

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
por: Takeuchi, Tsutomu, et al.
Publicado: (2016)

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
por: Cohen, Stanley, et al.
Publicado: (2017)

Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160
por: Smolen, Josef S, et al.
Publicado: (2012)

MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial
por: Behrens, Frank, et al.
Publicado: (2015)

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)
por: Quartier, Pierre, et al.
Publicado: (2010)

Randomised Double-Blind Trial of Combination Antibiotic Therapy in Rheumatoid Arthritis
por: Smith, Angela, et al.
Publicado: (2011)

Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks
por: Takeuchi, Tsutomu, et al.
Publicado: (2013)

Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial
por: Weinblatt, Michael E, et al.
Publicado: (2014)

Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study
por: Combe, B, et al.
Publicado: (2008)

Clinicopathologic and gastrointestinal effects of administration of prednisone, prednisone with omeprazole, or prednisone with probiotics to dogs: A double‐blind randomized trial
por: Rak, Mariola B., et al.
Publicado: (2023)

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
por: Salliot, C, et al.
Publicado: (2009)

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study
por: McInnes, Iain B, et al.
Publicado: (2015)

Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial
por: Reginster, Jean-Yves, et al.
Publicado: (2013)

Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)
por: Sieper, Joachim, et al.
Publicado: (2015)

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
por: Emery, P, et al.
Publicado: (2017)

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy
por: Emery, Paul, et al.
Publicado: (2017)

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
por: Burmester, Gerd R, et al.
Publicado: (2017)

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
por: Mease, P J, et al.
Publicado: (2014)

Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis
por: Peterfy, Charles, et al.
Publicado: (2016)

Efficacy and safety of modified-release prednisone in patients with rheumatoid arthritis
por: Krasselt, Marco, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_60b7poqqiqi686928kldnr446e